Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The FDA may be about to change everything for peptide research. Secretary RFK Jr. announced plans to move 14 peptides from Category 2 to Category 1. That means FDA recognized. Potentially prescribable through The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York